Patents by Inventor James Madison Ligon
James Madison Ligon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6858404Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: November 13, 2001Date of Patent: February 22, 2005Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Publication number: 20030068788Abstract: Disclosed is a family of P450 monooxygenases, each member of which regioselectively oxidizes avermectin to 4″-keto-avermectin. The P450 monooxgenases find use in methods and formulations for making emamectin from avermectin. Also disclosed are methods for purifying the P450 monooxygenases of the invention, binding agents that specifically bind to the P450 monooxygenases of the invention, and genetically engineered cells that express the P450 monooxygenases of the invention. Also disclosed are ferredoxins and ferredoxin reductases that are active with the P450 monooxygenases of the invention.Type: ApplicationFiled: May 14, 2002Publication date: April 10, 2003Inventors: Thomas Gunther Buckel, Philip Eugene Hammer, Dwight Steven Hill, James Madison Ligon, Istvan Molnar Durham, Johannes Paul Pachlatko, Ross Eric Zirkle
-
Publication number: 20020192778Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: ApplicationFiled: November 13, 2001Publication date: December 19, 2002Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
-
Patent number: 6383787Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: May 7, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6358719Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: March 19, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6355459Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: March 12, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6355457Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: March 12, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6355458Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: March 12, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6346404Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: May 10, 2000Date of Patent: February 12, 2002Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
-
Patent number: 6121029Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.Type: GrantFiled: June 17, 1999Date of Patent: September 19, 2000Assignee: Novartis AGInventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
-
Patent number: 6117670Abstract: The present invention is directed to the production of pyrrolnitrin in a host via recombinant expression of the polypeptides needed to biologically synthesize pyrrolnitrin. Genes isolated from P. fluorescens, P. pyrrocinia, B. cepacia, and M. fulvus that encode polypeptides necessary to produce pyrrolnitrin are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize pyrrolnitrin from any organism capable of producing pyrrolnitrin. The isolated genes may be transformed and expressed in a desired host organisms to produce pyrrolnitrin according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of pyrrolnitrin.Type: GrantFiled: February 24, 1998Date of Patent: September 12, 2000Assignee: Novartis Finance CorporationInventors: James Madison Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip Eugene Hammer, Karl-Heinz van Pee, Sabine Kirner, Thomas R. Young
-
Patent number: 5955348Abstract: Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.Type: GrantFiled: November 25, 1997Date of Patent: September 21, 1999Assignee: Novartis AGInventors: James Madison Ligon, Nancy R. Torkewitz, Dwight Steven Hill, Thomas Deane Gaffney, Jill Michelle Stafford